Effective integration of systems biology, biomarkers, biosimulation and modelling in streamlining drug development

European Journal of Pharmaceutical Sciences

Volumn 31, Issue 1, 2007, Pages 62-67

  Krishna, Rajesh ^a   Schaefer, Hans Guenter ^b   Bjerrum, Ole J ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Basel; Conference report; Modeling; Simulations; Systems biology

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; DECISION MAKING; DRUG RESEARCH; EUROPEAN UNION; HEALTH CARE ORGANIZATION; PRIORITY JOURNAL; PRODUCTIVITY; SCIENTIST; SIMULATION; SYSTEMS BIOLOGY; TECHNOLOGY;

EID: 34247167585     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2007.02.003     Document Type: Note

References (12)

1. Bjerrum O.J. New safe medicines faster: a proposal for a key action within the European union's 6th framework programme. Pharmacol. Toxicol. 86 Suppl. 1 (2000) 23-26
2. EFPIA, 2004. Innovative Medicines for Europe. Available at: http://ec.europa.eu/research/fp6/index_en.cfm?p=1_innomed. Accessed December 29, 2006.
3. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 3 8 (2004) 711-715
4. Krishna R. Introduction to dose optimization. In: Krishna R. (Ed). Dose Optimization in Drug Development vol. 161 (2006), Taylor and Francis 1-13
5. Krishna R. Quantitative clinical pharmacology: making paradigm shifts a reality. J. Clin. Pharmacol. 46 9 (2006) 966-967
6. Lesko L., Rowland M., Peck C.C., and Blashcke T. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Eur. J. Pharm. Sci. 10 4 (2000) 4-14
7. New Safe Medicines Faster, 2000. Proposals for research topics, methodologies, techniques and other means of promoting for the drug development process to the benefit of European citizens. Available at http://eufeps.org. Accessed December 29, 2006.
8. New Safe Medicines Faster. How to rethink and accelerate the development and approval of innovative new medicines for faster patient relief, 2003. Available at http://eufeps.org. Accessed December 29. 2006.
9. Rolan P., Atkinson A., and Lesko L. Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin. Pharmacol. Ther. 73 4 (2003) 284-291
10. Stanski D.R., Rowland M., and Sheiner L.B. Getting the dose right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development. J. Pharmacokinet. Pharmacodyn. 32 2 (2005) 199-211
11. Tucker G.T., Houston J.B., and Huang S.M. EUFEPS conference report. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential-towards a consensus. European Federation of Pharmaceutical Sciences. Eur. J. Pharm. Sci. 13 4 (2001) 417-428
12. US Food and Drug Administration, 2004. Challenge and Opportunity on the Critical Path to New Medical Products. Available at: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html. Accessed December 29, 2006.